New strategy for monitoring targeted therapy: Molecular imaging

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3703-3713

  Teng, Fei Fei ^a   Meng, Xue ^a   Sun, Xin Dong ^a   Yu, Jin Ming ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

CT; Molecular imaging; MRI; PET; Targeted therapy; US

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; ANTINEOPLASTIC AGENT; BAY 853474; CARBON 11; ERLOTINIB; FLUORINE; FLUORINE 18; FLUOROAZOMYCIN ARABINOFURANOSIDE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; FLUOROETANIDAZOLE F 18; GADOLINIUM; GEFITINIB; IODINE 124; IODOAZOMYCINARABINOSIDE F 18; LIPOSOME; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; NANOCARRIER; PD 032590121; PENTETIC ACID DERIVATIVE; PHOSPHORUS 31; PKI 16620; PROTEIN TYROSINE KINASE INHIBITOR; RADIOISOTOPE; TETRAXETAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIRCONIUM 89;

CANCER PROGNOSIS; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DRUG ACCUMULATION; DRUG HALF LIFE; ECHOGRAPHY; GENE MUTATION; HUMAN; IN VIVO STUDY; INVASIVE PROCEDURE; LUNG CANCER; MICROBUBBLE; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; QUANTITATIVE ASSAY; REVIEW; STOMACH CANCER; TUMOR VOLUME;

CT; MOLECULAR IMAGING; MRI; PET; TARGETED THERAPY; US;

ANIMALS; HUMANS; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY; NANOPARTICLES; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84885034519     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S51264     Document Type: Review

References (87)

1. Hoogerwerf MA, Ninaber MK, Willems LN, Kaptein AA. "Feelings are facts": illness perceptions in patients with lung cancer. Respir Med. 2012;106(8):1170-1176.
2. Tolmachev V, Stone-Elander S, Orlova A. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol. 2010;11(10):992-1000.
3. Eisenhauer EA, Therasse P, Bogaerts J, etal. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
4. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol. 2004;22(22):4442-4445.
5. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol. 2002;20(22):4478-4484.
6. Zhang J, Huang Y, Li X, etal. The impact of tumor size change after target therapy on survival: analysis of patients enrolled onto three clinical trials of advanced NSCLC from one institution. Onco Targets Ther. 2012;5:349-355.
7. van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist. 2007;12(12):1379-1389.
8. van Dongen GA, Vosjan MJ. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm. 2010;25(4):375-385.
9. de Vries EG, Oude Munnink TH, van Vugt MA, Nagengast WB. Toward molecular imaging-driven drug development in oncology. Cancer Discov. 2011;1(1):25-28.
10. Ou SH. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther. 2011;5:471-485.
11. Moon YW, Park S, Sohn JH, etal. Clinical significance of progesterone receptor and HER2status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. J Cancer Res Clin Oncol. 2011;137(7): 1123-1130.
12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology(tm): Breast Cancer. Fort Washington, PA: National Comprehensive Cancer Network; 2011.
13. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol. 2004;22(23):4772-4778.
14. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer. 2005;93(5):552-556.
15. Sirera R, Bremnes RM, Cabrera A, etal. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011;6(2):286-290.
16. Zhao X, Han RB, Zhao J, etal. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients. Respiration. 2013;85(2):119-125.
17. Mankoff DA. Molecular imaging to select cancer therapy and evaluate treatment response. Q J Nucl Med Mol Imaging. 2009;53(2): 181-192.
18. Blasberg RG, Tjuvajev JG. Molecular-genetic imaging: current and future perspectives. J Clin Invest. 2003;111(11):1620-1629.
19. Buck AK, Reske SN. Cellular origin and molecular mechanisms of 18F-FDG uptake: is there a contribution of the endothelium? J Nucl Med. 2004;45(3):461-463.
20. Zander T, Scheffler M, Nogova L, etal. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol. 2011;29(13): 1701-1708.
21. Kahraman D, Scheffler M, Zander T, etal. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3′-deoxy-3′-18F-fluorothymidine PET. J Nucl Med. 2011;52(12):1871-1877.
22. Ullrich RT, Zander T, Neumaier B, etal. Early detection of erlotinib treatment response in NSCLC by 3′-deoxy-3′-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). PLoS ONE. 2008; 3(12):e3908.
23. Yue J, Chen L, Cabrera AR, etal. Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study. J Nucl Med. 2010;51(4):528-534.
24. Scheffler M, Zander T, Nogova L, etal. Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib. PLoS ONE. 2013;8(1):e53081.
25. Kobe C, Scheffler M, Holstein A, etal. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. Eur J Nucl Med Mol Imaging. 2012;39(7): 1117-1127.
26. Kahraman D, Holstein A, Scheffler M, etal. Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib. Clin Nucl Med. 2012;37(11):1058-1064.
27. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S-150S.
28. Wiehr S, von Ahsen O, Röse L, etal. Preclinical evaluation of a novel c-Met inhibitor in a gastric cancer xenograft model using small animal PET. Mol Imaging Biol. 2013;15(2):203-211.
29. Kasper B, Dimitrakopoulou-Strauss A, Pilz LR, Strauss LG, Sachpekidis C, Hohenberger P. Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib. Biomed Res Int. 2013;2013:389672.
30. Solit DB, Santos E, Pratilas CA, etal. 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res. 2007;67(23):11463-11469.
31. Waldherr C, Mellinghoff IK, Tran C, etal. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET. J Nucl Med. 2005;46(1):114-120.
32. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008;49 Suppl 2:129S-148S.
33. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol. 2011;101(3): 369-375.
34. Li Z, Chu T. Recent advances on radionuclide labeled hypoxia-imaging agents. Curr Pharm Des. 2012;18(8):1084-1097.
35. Mileshkin L, Hicks RJ, Hughes BG, etal. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res. 2011;17(10):3304-3315.
36. Takahashi R, Hirata H, Tachibana I, etal. Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res. 2012;18(1):220-228.
37. Bengtsson T, Hicks RJ, Peterson A, Port RE. 18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value. J Nucl Med. 2012;53(4):530-537.
38. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17(5):545-580.
39. van Dongen GA, Poot AJ, Vugts DJ. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour Biol. 2012;33(3):607-615.
40. Tijink BM, Perk LR, Budde M, etal. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging. 2009;36(8):1235-1244.
41. Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44(8):1271-1281.
42. Dijkers EC, Oude Munnink TH, Kosterink JG, etal. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87(5):586-592.
43. van der Bilt AR, Terwisscha van Scheltinga AG, Timmer-Bosscha H, et al. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. Clin Cancer Res. 2012;18(22):6306-6314.
44. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med. 2006;47(5):793-796.
45. Kenanova V, Wu AM. Tailoring antibodies for radionuclide delivery. Expert Opin Drug Deliv. 2006;3(1):53-70.
46. Cuartero-Plaza A, Martínez-Miralles E, Rosell R, Vadell-Nadal C, Farré M, Real FX. Radiolocalization of squamous lung carcinoma with 131I-labeled epidermal growth factor. Clin Cancer Res. 1996;2(1):13-20.
47. Zhang Y, Hong H, Niu G, etal. Positron emission tomography imaging of vascular endothelial growth factor receptor expression with (61)Cu-labeled lysine-tagged VEGF(121). Mol Pharm. Epub November 16, 2012.
48. Gelovani JG. Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography. Cancer Metastasis Rev. 2008;27(4):645-653.
49. Memon AA, Weber B, Winterdahl M, etal. PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer. Br J Cancer. 2011;105(12):1850-1855.
50. Meng X, Loo BW Jr, Ma L, Murphy JD, Sun X, Yu J. Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study. J Nucl Med. 2011;52(10): 1573-1579.
51. Slobbe P, Poot AJ, Windhorst AD, van Dongen GA. PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET. Drug Discov Today. 2012;17(21-22):1175-1187.
52. Miao Z, Levi J, Cheng Z. Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids. 2011;41(5):1037-1047.
53. Orlova A, Magnusson M, Eriksson TL, etal. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006;66(8):4339-4348.
54. Friedman M, Orlova A, Johansson E, etal. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol. 2008;376(5):1388-1402.
55. Lindborg M, Cortez E, Höidén-Guthenberg I, etal. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor β in vivo. J Mol Biol. 2011;407(2):298-315.
56. Miao Z, Ren G, Liu H, Jiang L, Cheng Z. Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein. Bioconjug Chem. 2010;21(5):947-954.
57. Miao Z, Ren G, Liu H, Jiang L, Cheng Z. Cy5.5-labeled Affibody molecule for near-infrared fluorescent optical imaging of epidermal growth factor receptor positive tumors. J Biomed Opt. 2010;15(3):036007.
58. Orlova A, Tolmachev V, Pehrson R, etal. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 2007;67(5):2178-2186.
59. Kramer-Marek G, Kiesewetter DO, Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J Nucl Med. 2009;50(7):1131-1139.
60. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99(9):2293-2352.
61. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 1998;4(5):623-626.
62. Boles KS, Schmieder AH, Koch AW, etal. MR angiogenesis imaging with Robo4-vs alphaVbeta3-targeted nanoparticles in a B16/F10mouse melanoma model. FASEB J. 2010;24(11):4262-4270.
63. Mulder WJ, Strijkers GJ, van Tilborg GA, Griffioen AW, Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed. 2006;19(1):142-164.
64. Mulder WJ, van der Schaft DW, Hautvast PA, etal. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J. 2007;21(2):378-383.
65. Guimaraes A R, Ross R, Figuereido J L, Waterman P, Weissleder R. MRI with magnetic nanoparticles monitors downstream anti-angiogenic effects of mTOR inhibition. Mol Imaging Biol. 2011;13:314-320.
66. Abdolahi M, Shahbazi-Gahrouei D, Laurent S, et al. Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer. Contrast Media Mol Imaging. 2013; 8:175-184.
67. Ward KM, Aletras AH, Balaban RS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J Magn Reson. 2000;143(1):79-87.
68. Liu G, Liang Y, Bar-Shir A, etal. Monitoring enzyme activity using a diamagnetic chemical exchange saturation transfer magnetic resonance imaging contrast agent. J Am Chem Soc. 2011;133(41):16326-16329.
69. Gilad AA, van Laarhoven HW, McMahon MT, etal. Feasibility of concurrent dual contrast enhancement using CEST contrast agents and superparamagnetic iron oxide particles. Magn Reson Med. 2009;61(4): 970-974.
70. Terreno E, Barge A, Beltrami L, etal. Highly shifted LIPOCEST agents based on the encapsulation of neutral polynuclear paramagnetic shift reagents. Chem Commun (Camb). 2008:600-602.
71. Glunde K, Bhujwalla ZM. Metabolic tumor imaging using magnetic resonance spectroscopy. Semin Oncol. 2011;38(1):26-41.
72. Beloueche-Babari M, Jackson LE, Al-Saffar NM, Workman P, Leach MO, Ronen SM. Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Res. 2005;65(8):3356-3363.
73. Klawitter J, Anderson N, Klawitter J, etal. Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study. Br J Cancer. 2009;100(6):923-931.
74. Sankaranarayanapillai M, Tong WP, Yuan Q, etal. Monitoring histone deacetylase inhibition in vivo: noninvasive magnetic resonance spectroscopy method. Mol Imaging. 2008;7(2):92-100.
75. Kato Y, Okollie B, Artemov D. Noninvasive 1H/13C magnetic resonance spectroscopic imaging of the intratumoral distribution of temozolomide. Magn Reson Med. 2006;55(4):755-761.
76. Howe FA, Robinson SP, Rodrigues LM, Griffiths JR. Flow and oxygenation dependent (FLOOD) contrast MR imaging to monitor the response of rat tumors to carbogen breathing. Magn Reson Imaging. 1999;17(9):1307-1318.
77. Unnikrishnan S, Klibanov AL. Microbubbles as ultrasound contrast agents for molecular imaging: preparation and application. AJR Am J Roentgenol. 2012;199(2):292-299.
78. Anderson CR, Hu X, Zhang H, etal. Ultrasound molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent. Invest Radiol. 2011;46(4):215-224.
79. Willmann JK, Kimura RH, Deshpande N, Lutz AM, Cochran JR, Gambhir SS. Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J Nucl Med. 2010;51(3):433-440.
80. Willmann JK, Paulmurugan R, Chen K, etal. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2in mice. Radiology. 2008;246(2):508-518.
81. Anderson CR, Rychak JJ, Backer M, Backer J, Ley K, Klibanov AL. scVEGF microbubble ultrasound contrast agents: a novel probe for ultrasound molecular imaging of tumor angiogenesis. Invest Radiol. 2010;45(10):579-585.
82. Warram JM, Sorace AG, Saini R, Umphrey HR, Zinn KR, Hoyt K. A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature. J Ultrasound Med. 2011;30(7):921-931.
83. Deshpande N, Ren Y, Foygel K, Rosenberg J, Willmann J K. Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging. Radiology. 2011; 258: 804-811.
84. Rabin O, Manuel Perez J, Grimm J, Wojtkiewicz G, Weissleder R. An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater. 2006;5(2):118-122.
85. Hyafil F, Cornily JC, Feig JE, etal. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med. 2007;13(5):636-641.
86. Jackson PA, Rahman WN, Wong CJ, Ackerly T, Geso M. Potential dependent superiority of gold nanoparticles in comparison to iodinated contrast agents. Eur J Radiol. 2010;75(1):104-109.
87. Aydogan B, Li J, Rajh T, etal. AuNP-DG: deoxyglucose-labeled gold nanoparticles as X-ray computed tomography contrast agents for cancer imaging. Mol Imaging Biol. 2010;12(5):463-467.